Publications by authors named "O O Olowokure"
Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.
Qual Life Res
October 2024
Article Synopsis
- The NRG/RTOG 0436 study investigated whether adding cetuximab to chemoradiation for non-operative esophageal cancer would improve patient-reported outcomes (PROs), focusing on the FACT-Esophageal cancer subscale (ECS).
- The study was stopped early due to failing to meet overall survival (OS) targets; among 344 enrolled patients, those receiving CRT plus cetuximab showed less improvement in ECS compared to those receiving standard CRT alone (37% vs. 53%).
- Overall, the results indicated that adding cetuximab did not enhance PROs related to symptoms, swallowing, or eating, and there was no significant link between clinical complete
Article Synopsis
- In April 2023, the National Comprehensive Cancer Network recommended neoadjuvant immunotherapy for certain patients with nonmetastatic mismatch repair deficient colon cancer, a subtype that comprises about 15% of colon cancers and responds well to immune treatments.
- A review of the literature identified 8 relevant studies out of 7691, focusing on safety and efficacy of this treatment, which included diverse agents and treatment durations.
- Results showed high rates of complete surgical resection (98%-100%) and significant pathological response rates (50%-91% achieving ypT0N0), with manageable safety profiles as most adverse events were mild to moderate.
Background: Immune checkpoint inhibitors (ICIs) in the setting of liver transplant (LT) pose a risk of rejection and hold unclear benefit in both the neoadjuvant (pre-transplant) and post-transplant salvage setting. In the pre-transplant setting, neoadjuvant ICIs may serve as a bridge to LT by downstaging disease burden to fit within transplant criteria. Outcomes in this setting include patients who had successful transplants without complications to patients who suffered severe complications, including fatal hepatic necrosis and graft failure requiring re-transplant.
View Article and Find Full Text PDFPurpose: The purpose of this trial was to assess the patient and physician-reported toxicity in anal cancer patients undergoing definitive chemoradiation with intensity-modulated proton therapy (IMPT).
Methods: Patients with stage II and III anal cancer were treated with IMPT. All patients received 2 cycles of 5-fluorouracil and mitomycin concurrently with radiation.
Background: The 5-year overall survival of pancreas adenocarcinoma (PCa) remains less than 10%. Clinical and tumor genomic characteristics have not differentiated PCa long-term survivors (LTSs) from unselected patients. Preclinical studies using fecal transplant experiments from LTSs of PCa have revealed delayed tumor growth through unknown mechanisms involving the fecal microbiota.
View Article and Find Full Text PDF